Success Metrics

Clinical Success Rate
93.5%

Based on 58 completed trials

Completion Rate
94%(58/62)
Active Trials
8(9%)
Results Posted
28%(16 trials)
Terminated
4(5%)

Phase Distribution

Ph early_phase_1
1
1%
Ph not_applicable
23
27%
Ph phase_1
5
6%
Ph phase_3
13
15%
Ph phase_2
9
10%
Ph phase_4
30
35%

Phase Distribution

6

Early Stage

9

Mid Stage

43

Late Stage

Phase Distribution81 total trials
Early Phase 1First-in-human
1(1.2%)
Phase 1Safety & dosage
5(6.2%)
Phase 2Efficacy & side effects
9(11.1%)
Phase 3Large-scale testing
13(16.0%)
Phase 4Post-market surveillance
30(37.0%)
N/ANon-phased studies
23(28.4%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

92.1%

58 of 63 finished

Non-Completion Rate

7.9%

5 ended early

Currently Active

8

trials recruiting

Total Trials

86

all time

Status Distribution
Active(12)
Completed(58)
Terminated(5)
Other(11)

Detailed Status

Completed58
unknown11
Terminated4
Active, not recruiting4
Recruiting4
Not yet recruiting4

Development Timeline

Analytics

Development Status

Total Trials
86
Active
8
Success Rate
93.5%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (1.2%)
Phase 15 (6.2%)
Phase 29 (11.1%)
Phase 313 (16.0%)
Phase 430 (37.0%)
N/A23 (28.4%)

Trials by Status

terminated45%
withdrawn11%
active_not_recruiting45%
recruiting45%
completed5867%
not_yet_recruiting45%
unknown1113%

Recent Activity

Clinical Trials (86)

Showing 20 of 86 trialsScroll for more
NCT03592212

Phosphodiesterase 4 Gene Variant and Salbutamol Response in Persistent Childhood Asthma

Terminated
NCT07037511Not Applicable

Effects of Salbutamol in Athletes and Implications for Screening and Sports

Recruiting
NCT06473779Phase 3

Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma.

Active Not Recruiting
NCT01958814Phase 2

Beta Agonist Nebulization in Non Invasively Ventilated COPD Patients: Safety, and Therapeutic Efficacy Range.

Completed
NCT06036823Phase 4

5 Versus 10 Units of Insulin in Hyperkalemia Management

Completed
NCT05527704Phase 3

the Inhaled β2-adrenergic Receptor Agonist for Transient Tachypnoea of the Newborn (the REFSAL Trial)

Active Not Recruiting
NCT03556683Not Applicable

Phase I Assessment of Hypertonic Saline in Moderate to Severe Asthmatics

Completed
NCT05457868

Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM) - Salbutamol vs Long-acting Muscarinic Antagonists

Completed
NCT05667727Phase 4

The Effect of Nebulized Epinephrine in Asthma Exacerbation in Pediatric Age Group With the Standard Treatment Compared to Standard Treatment Using Improvement PRAM Score as a Primary Outcome

Completed
NCT05653024Phase 3

INhaled Salbutamol vs Placebo for the Treatment of Acute IgE-mediated Abdominal Pain From Allergic Food REactions

Terminated
NCT03522831Not Applicable

CF Bronchodilation

Active Not Recruiting
NCT05087693Phase 4

Salbutamol Use in Ozone Air Pollution by People With Asthma and/or Exercise Induced Bronchoconstriction (EIB)

Completed
NCT06093152

Video Assisted Study of Salbutamol Response in Viral Wheezing

Recruiting
NCT04276233Phase 4

Efficacy and Safety Study of Mepolizumab 100 Milligram (mg) Subcutaneous (SC) in Indian Participants Aged Greater Than or Equal to (>=) 18 Years With Severe Eosinophilic Asthma

Completed
NCT03562195Phase 3

A Safety and Efficacy Study of Mepolizumab in Subjects With Severe Asthma

Completed
NCT03199976Phase 4

Efficacy of Intermittent Tiotropium in Early Childhood Wheezing

Terminated
NCT06482294Phase 2

CIVETTA: Correlating Inflammatory Values of FEno, SympToms, SpuTum and Lung Function in Asthma

Active Not Recruiting
NCT06426082Not Applicable

Deciphering a Novel and Unique Brown Adipose Tissue Depot in Women

Not Yet Recruiting
NCT04012138Phase 4

Insulin Dextrose Infusion vs Nebulized Salbutamol vs Combination of Salbutamol and Insulin Dextrose in Acute Hyperkalemia

Recruiting
NCT05860244Phase 2

Effect of Salbutamol on Walking Capacity in Ambulatory ALS Patients

Not Yet Recruiting

Drug Details

Intervention Type
DRUG
Total Trials
86